Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies

Hsin Yi Tung, Yu Cheng Su, Bing Mae Chen, Pierre Alain Burnouf, Wei Chiao Huang, Kuo Hsiang Chuang, Yu Ting Yan, Tian Lu Cheng, Steve R. Roffler

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Polyethylene glycol (PEG) is attached to many peptides, proteins, liposomes, and nanoparticles to reduce their immunogenicity and improve their pharmacokinetic and therapeutic properties. Here, we describe hybrid antibodies that can selectively deliver PEGylated medicines, imaging agents, or nanomedicines to target cells. Human IgG1 hybrid antibodies αPEG:αHER2 and αPEG:a CD19were shown by ELISA, FACS, and plasmonresonance to bind to both PEG and HER2 receptors on SK-BR-3 breast adenocarcinoma and BT-474 breast ductal carcinoma cells or CD19 receptors on Ramos and Raji Burkitt's lymphoma cells. In addition, αPEG:α HER2 specifically targeted PEGylated proteins, liposomes, and nanoparticles to SK-BR-3 cells that overexpressed HER2, but not toHER2-negativeMCF-7 breast adenocarcinoma cells. Endocytosis of PEGylated nanoparticles into SK-BR-3 cells was induced specifically by the αPEG:αHER2 hybrid antibody, as observed by confocal imaging of the accumulation of Qdots inside SK-BR-3 cells. Treatment of HER2+ SK-BR-3 and BT-474 cancer cells with αPEG:α HER2 and the clinically used chemotherapeutic agent PEGylated liposomal doxorubicin for 3 hours enhanced the in vitro effectiveness of PEGylated liposomal doxorubicin by over two orders of magnitude. Hybrid anti-PEG antibodies offer a versatile and simple method to deliver PEGylated compounds to cellular locations and can potentially enhance the therapeutic efficacy of PEGylated medicines.

Original languageEnglish
Pages (from-to)1317-1326
Number of pages10
JournalMolecular Cancer Therapeutics
Volume14
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Antibodies
Neoplasms
Nanoparticles
Liposomes
Adenocarcinoma
Breast
Nanomedicine
Carcinoma, Ductal, Breast
Burkitt Lymphoma
Endocytosis
Proteins
Therapeutics
Pharmacokinetics
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Peptides
liposomal doxorubicin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies. / Tung, Hsin Yi; Su, Yu Cheng; Chen, Bing Mae; Burnouf, Pierre Alain; Huang, Wei Chiao; Chuang, Kuo Hsiang; Yan, Yu Ting; Cheng, Tian Lu; Roffler, Steve R.

In: Molecular Cancer Therapeutics, Vol. 14, No. 6, 01.06.2015, p. 1317-1326.

Research output: Contribution to journalArticle

Tung, HY, Su, YC, Chen, BM, Burnouf, PA, Huang, WC, Chuang, KH, Yan, YT, Cheng, TL & Roffler, SR 2015, 'Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies', Molecular Cancer Therapeutics, vol. 14, no. 6, pp. 1317-1326. https://doi.org/10.1158/1535-7163.MCT-15-0151
Tung, Hsin Yi ; Su, Yu Cheng ; Chen, Bing Mae ; Burnouf, Pierre Alain ; Huang, Wei Chiao ; Chuang, Kuo Hsiang ; Yan, Yu Ting ; Cheng, Tian Lu ; Roffler, Steve R. / Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 6. pp. 1317-1326.
@article{c149b417a96348288bd5b777302b27d3,
title = "Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies",
abstract = "Polyethylene glycol (PEG) is attached to many peptides, proteins, liposomes, and nanoparticles to reduce their immunogenicity and improve their pharmacokinetic and therapeutic properties. Here, we describe hybrid antibodies that can selectively deliver PEGylated medicines, imaging agents, or nanomedicines to target cells. Human IgG1 hybrid antibodies αPEG:αHER2 and αPEG:a CD19were shown by ELISA, FACS, and plasmonresonance to bind to both PEG and HER2 receptors on SK-BR-3 breast adenocarcinoma and BT-474 breast ductal carcinoma cells or CD19 receptors on Ramos and Raji Burkitt's lymphoma cells. In addition, αPEG:α HER2 specifically targeted PEGylated proteins, liposomes, and nanoparticles to SK-BR-3 cells that overexpressed HER2, but not toHER2-negativeMCF-7 breast adenocarcinoma cells. Endocytosis of PEGylated nanoparticles into SK-BR-3 cells was induced specifically by the αPEG:αHER2 hybrid antibody, as observed by confocal imaging of the accumulation of Qdots inside SK-BR-3 cells. Treatment of HER2+ SK-BR-3 and BT-474 cancer cells with αPEG:α HER2 and the clinically used chemotherapeutic agent PEGylated liposomal doxorubicin for 3 hours enhanced the in vitro effectiveness of PEGylated liposomal doxorubicin by over two orders of magnitude. Hybrid anti-PEG antibodies offer a versatile and simple method to deliver PEGylated compounds to cellular locations and can potentially enhance the therapeutic efficacy of PEGylated medicines.",
author = "Tung, {Hsin Yi} and Su, {Yu Cheng} and Chen, {Bing Mae} and Burnouf, {Pierre Alain} and Huang, {Wei Chiao} and Chuang, {Kuo Hsiang} and Yan, {Yu Ting} and Cheng, {Tian Lu} and Roffler, {Steve R.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-15-0151",
language = "English",
volume = "14",
pages = "1317--1326",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Selective delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies

AU - Tung, Hsin Yi

AU - Su, Yu Cheng

AU - Chen, Bing Mae

AU - Burnouf, Pierre Alain

AU - Huang, Wei Chiao

AU - Chuang, Kuo Hsiang

AU - Yan, Yu Ting

AU - Cheng, Tian Lu

AU - Roffler, Steve R.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Polyethylene glycol (PEG) is attached to many peptides, proteins, liposomes, and nanoparticles to reduce their immunogenicity and improve their pharmacokinetic and therapeutic properties. Here, we describe hybrid antibodies that can selectively deliver PEGylated medicines, imaging agents, or nanomedicines to target cells. Human IgG1 hybrid antibodies αPEG:αHER2 and αPEG:a CD19were shown by ELISA, FACS, and plasmonresonance to bind to both PEG and HER2 receptors on SK-BR-3 breast adenocarcinoma and BT-474 breast ductal carcinoma cells or CD19 receptors on Ramos and Raji Burkitt's lymphoma cells. In addition, αPEG:α HER2 specifically targeted PEGylated proteins, liposomes, and nanoparticles to SK-BR-3 cells that overexpressed HER2, but not toHER2-negativeMCF-7 breast adenocarcinoma cells. Endocytosis of PEGylated nanoparticles into SK-BR-3 cells was induced specifically by the αPEG:αHER2 hybrid antibody, as observed by confocal imaging of the accumulation of Qdots inside SK-BR-3 cells. Treatment of HER2+ SK-BR-3 and BT-474 cancer cells with αPEG:α HER2 and the clinically used chemotherapeutic agent PEGylated liposomal doxorubicin for 3 hours enhanced the in vitro effectiveness of PEGylated liposomal doxorubicin by over two orders of magnitude. Hybrid anti-PEG antibodies offer a versatile and simple method to deliver PEGylated compounds to cellular locations and can potentially enhance the therapeutic efficacy of PEGylated medicines.

AB - Polyethylene glycol (PEG) is attached to many peptides, proteins, liposomes, and nanoparticles to reduce their immunogenicity and improve their pharmacokinetic and therapeutic properties. Here, we describe hybrid antibodies that can selectively deliver PEGylated medicines, imaging agents, or nanomedicines to target cells. Human IgG1 hybrid antibodies αPEG:αHER2 and αPEG:a CD19were shown by ELISA, FACS, and plasmonresonance to bind to both PEG and HER2 receptors on SK-BR-3 breast adenocarcinoma and BT-474 breast ductal carcinoma cells or CD19 receptors on Ramos and Raji Burkitt's lymphoma cells. In addition, αPEG:α HER2 specifically targeted PEGylated proteins, liposomes, and nanoparticles to SK-BR-3 cells that overexpressed HER2, but not toHER2-negativeMCF-7 breast adenocarcinoma cells. Endocytosis of PEGylated nanoparticles into SK-BR-3 cells was induced specifically by the αPEG:αHER2 hybrid antibody, as observed by confocal imaging of the accumulation of Qdots inside SK-BR-3 cells. Treatment of HER2+ SK-BR-3 and BT-474 cancer cells with αPEG:α HER2 and the clinically used chemotherapeutic agent PEGylated liposomal doxorubicin for 3 hours enhanced the in vitro effectiveness of PEGylated liposomal doxorubicin by over two orders of magnitude. Hybrid anti-PEG antibodies offer a versatile and simple method to deliver PEGylated compounds to cellular locations and can potentially enhance the therapeutic efficacy of PEGylated medicines.

UR - http://www.scopus.com/inward/record.url?scp=84942091825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942091825&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-15-0151

DO - 10.1158/1535-7163.MCT-15-0151

M3 - Article

C2 - 25852063

AN - SCOPUS:84942091825

VL - 14

SP - 1317

EP - 1326

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -